Phaseline

Companies › iOnctura

iOnctura: clinical trials, targets and expected readouts

1 active drug program in 7 registered trials: 6 Phase 1, 1 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
roginolisib (IOA-244)
PI3K inhibitor
PIK3CAPhase 2Uveal Melanoma; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Myelofibrosis (MF); Solid Tumor, Adult …Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06879717roginolisib (IOA-244)Phase 1Non-Squamous Non-Small Cell Lung Cancer (NSCLC)OncologyJan 2027
NCT07203391roginolisib (IOA-244)Phase 1Uveal Melanoma, MetastaticOncologyDec 2027
NCT06717126roginolisib (IOA-244)Phase 2Uveal MelanomaOncologyDec 2027
NCT06887803roginolisib (IOA-244)Phase 1Myelofibrosis (MF)OncologyMar 2028
NCT04328844roginolisib (IOA-244)Phase 1Solid Tumor, AdultOncologyMar 2028
NCT07018752roginolisib (IOA-244)Phase 1Peripheral T Cells Lymphoma (PTCL)OncologyApr 2028
NCT06644183roginolisib (IOA-244)Phase 1LeukemiaOncologyOct 2028

Targets

PIK3CA (1)

Companies with the same targets

Eli Lilly Novartis Recursion Pharmaceuticals TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Totus Medicines Risen (Suzhou) Pharma Tech Restorbio Roche Haihe Biopharma Faeth Therapeutics

Companies built like this

Risen (Suzhou) Pharma Tech Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.